Completed PHASE4 INTERVENTIONAL NCT00227500

Pravastatin for Hyperlipidaemia in HIV.

A Randomised, Double-Blind Study of Pravastatin for the Treatment of Hyperlipidaemia in Patients With HIV

Sponsor: Garvan Institute of Medical Research

Conditions Cardiovascular Disease Glucose Metabolism HIV Infections Lipid Metabolism Lipodystrophy Metabolic Abnormality

Interventions Pravastatin

Updated 5 times since 2017 Last updated: Jun 8, 2006 Started: Jul 31, 2001 Completion: Oct 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Cardiovascular Disease and Glucose Metabolism, this trial is completed. The trial is conducted by Garvan Institute of Medical Research and has accumulated 5 data snapshots since 2001. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jul 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Garvan Institute of Medical Research
Kirby Institute
National Heart, Lung, and Blood Institute (NHLBI)
St Vincent's Hospital, Sydney
The University of New South Wales

Data source: Kirby Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sydney, Australia